Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-05-15
2007-05-15
Harris, Alana M. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S004000, C435S007100, C435S007210, C435S183000, C436S063000, C436S064000, C436S086000, C436S174000, C436S536000
Reexamination Certificate
active
10177296
ABSTRACT:
Acquired and de novo endocrine resistance are major clinical problems in the management of breast cancer patients. Though the antiestrogen tamoxifen prolongs disease-free and overall survival in the adjuvant setting, and induces remissions in over half of the patients with estrogen receptor positive metastatic disease, all patients eventually acquire tamoxifen resistance. Furthermore, many of the resistant tumors actually appear to be stimulated by tamoxifen just as they are by estrogens. The present invention provides methods of predicting endocrine resistance comprising detecting the biological activity and/or expression of p38 MAPK and/or AIB1. The invention further provides methods of reducing, reversing, or preventing endocrine resistance comprising contacting a breast or prostate tumor with a p38 MAPK pathway inhibitor.
REFERENCES:
patent: 5836905 (1998-11-01), Lemelson et al.
patent: WO 00/34788 (2000-06-01), None
Lee et al. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmocology 47: 185-201, 2000.
Gutierrez et al. Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen -Activated Protein Kinase. Journal of Clinical Oncology 23(11): 2469-2476, Apr. 10, 2005.
Dumas J, et al., 2002, “Synthesis and Pharmacological Characterization of a Potent, Orally Active p38 Kinase Inhibitor”Bioorg Med Chem Letters12:1559-1562.
Massarweh S et al., 2002, “Inhibition of epidermal growth factor/HER2 receptor signaling using ZD1839 (‘Iressa’) restores tamoxifen sensitivity and delays resistance to estrogen deprivation in HER2-overexpression breast tumors”Proceedings of ASCO21:33a (Abstract 130).
Osborne CK et al., 2002, “The estrogen receptor coactivator ALBI (SRC3) in combination with HER-2 is a prognostic and predictive marker in patients with breast cancer”Proceedings of ASCO21:33a (Abstract 129).
Shou J et al., 2002, “The selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (‘Iressa’) blocks estrogen receptor/growth factor cross-talk implicated in tamoxifen resistance in breast cancer”American Association for Cancer Research,93rd Annual Meeting, Apr. 6-10, 2002, San Francisco CA (Abstract 4964).
Barone et al., 2001, “Inhhibition of p38 Mitogen-Activated Protein Kinase Provides Neuroprotection in Cerebral Focal Ischemia”Med Res Rev.21(2):129-145.
Driggers PH et al., 2001, “The Proto-oncoprotein Brx Activates Estrogen Receptor β by a p38 Mitogen-activated Prot Kinase Pathway”J. Biol. Chem.276(50):46792-46797.
Jacobs A et al., 2001, “Quantitative Kinetics of [124]FIAU in Cat and Man”J Nucl Med42(3):467-475.
Legos et al., 2001, “SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia”Brain Res.892:70-77.
McLay LM et al., 2001, “The Discovery of RPR 200765A, a p38 MAP Kinase Inhibitor Displaying a Good Oral Anti-Arthritic Efficacy”Bioorg Med Chem.9:537-554.
Shou J et al., 2001, “Onset of endocrine resistance in breast cancer is associated with increased active p38 MAPK”Breast Cancer Res Treat69:254 (Abstract 272).
Katzenellenbogen BS et al., 2000, “Estrogen Receptors: Selective Ligands, Partners, and Distinctive Pharmacology”Recent Progress In Hormones Res55:163-195.
Lee et al., 2000, “MEKK1 Activation of Human Estrogen Receptor α and Stimulation of the Agonistic Activity of 4-Hydroxytamoxifen in Endometrial and Ovarian Cancer Cells” ,Mol Endocrinol.14(11):1882-1896.
Schiff R et al., 2000, Oxidative Stress and AP-1 Activity in Tamoxifen-Resistant Breast TumorsIn Vivo, J Natl Cancer Inst92(23):1926-1934.
Wunderbaldinger P et al., 2000, “New approaches for imaging in gene therapy”Eur J Radiol34:156-165.
Thompson S et al., 1999, “MAP kinase-mediated signalling to nucleosomes and immediate-early gene induction”,Cell Dev. Biol.10:205-214.
Löfberg M et al., 1998, “Antimyosin Scintigraphy Compared with Magnetic Resonance Imaging in Inflammatory Myopathies”Arch Neurol.55:987-993.
Osborne CK, 1998, “Tamoxifen In The Treatment of Breast Cancer”,N Engl J Med339(22):1609-1618.
Pierrat B et al., 1998, “ RSK-B, a novel ribosomal S6 kinase family member, is a CREB kinase under dominant control of p38α mitogen-activate protein kinase (p38αMAPK)”J. Biol. Chem.273(45):29661-29671.
Cuenda A, et al., 1996, “Purification and cDNA cloning of SAPKK3, the major activator of RK/p38 in stress- and cytokine-stimulated monocytes and epithelial cells”EMBO J.15(16):4156-4164.
Weigel N, 1996, “Steroid hormone receptors and their regulation by phosphorylation”Biochem J319:657-667.
Kato S et al., 1995, “Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase”Science270:1491-1494.
Osborne et al., 1995, “Comparison of the Effects of a Pure Steroidal Antiestrogen With Those of Tamoxifen in a Model of Human Breast Cancer”,J Natl Cancer Inst87(10):746-750.
Fujimoto N et al., 1994, “Alteration in the Agonist/Antagonist Balance of Antiestrogens by Activation of Protein Kinase A Signaling Pathways in Breast Cancer Cells: Antiestrogen Selectivity and Promoter Dependence”Mol Endocrinol.8(3):296-304.
Osborne CK et al., 1994, “Mechanisms of tamoxifen resistance”,Breast Cancer Res Treat.32:49-55.
Encarnación CA et al., 1993, “Measurement of steroid hormone receptors in breast cancer patients on tamoxifen”Breast Cancer Res. Treat.26:237-246.
Early Breast Cancer Trials Collaborative Group, 1992, “Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy”Lancet339(8785):71-85.
Osborne CK et al., 1991, “Acquired Tamoxifen Resistance: Correlation With Reduced Breast Tumor Levels of Tamoxifen and Isomerization of Trans-4-Hydroxytamoxifen”,J Natl Cancer Inst.83(20):1477-1482.
Saez R et al., 1989, Hormonal Treatment of Advanced Breast CancerHormone Therapy of Breast Cancer,pp. 163-172.
Osborne CK et al., 1987, “Human Breast Cancer in the Athymic Nude Mouse: Cytostatic Effects of Long-term Antiestrogen Therapy”Eur J Cancer Clin Oncol.23(8):1189-1196.
Hoogstraten B et al., 1984, Combined Modality Therapy for First Recurrence of Breast CancerCancer54(10):2248-2256.
Pritchard KI et al., 1980, “Tamoxifen Therapy in Premenopausal Patients With Metastatic Breast Cancer”Cancer Treat Rep.64(6-7):787-96.
Rabenoelina F et al., 2002, “Effect of prolonged hydroxytamoxifen treatment of MCF-7 cells on mitogen activated kinase cascade”Int J Cancer98(5):698-706.
Alsayed Y et al., 2001, “Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid”J Biol Chem276(6):4012-4019.
NCBI Accession No. AF012108; Aug. 19, 1997;Homo sapiensAmplified in Breast Cancer (AIBI) mRNA, Complete CDs; Last Accesses 5/25/206; www.ncbi.nlm.nih.gov; pp. 4.
NCBI Accession No. BD192354; Jul. 17, 2003; AIB1, A Steroid Receptor Co-Activator; Last Accessed May 25, 2006; www.ncbi.nlm.nih.gov; pp. 3.
NCBI Accession No. AAC51677; Aug. 13, 1997; Amplified in Breast Cancer [Homo Sapiens]; Last Accessed May 25, 2006; www.ncbi.nlm.nih.gov; pp. 2.
Anzick et al.; “AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer”; Science, vol. 277; pp. 965-968, Aug. 15, 1997.
NCBI Accession No. NP—001871; Mar. 19, 1999; cAMP Responsive Element Binding Protein 2 [Homo sapiens]; Last Accessed May 25, 2006; www.ncbi.nlm.nih.gov; pp. 2.
NCBI Accession No. NM—001880; Mar. 19, 1999;Homo SapienscAMP Responsive Element Binding Protein 2 (CREB2) mRNA; Last Accessed May 25, 2006; www.ncbi.nlm.nih.gov; pp. 2.
Maekawa et al.; “Leucine zipper structure of the protein CRE-BP1 binding to the cyclic AMP response element in brain”;EMBO J., vo
Osborne C. Kent
Schiff Rachel
Shou Jiang
Baylor College of Medicine
Harris Alana M.
LandOfFree
P38 MAPK pathway predicts endocrine-resistant growth of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with P38 MAPK pathway predicts endocrine-resistant growth of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and P38 MAPK pathway predicts endocrine-resistant growth of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3766729